Clinical Trial Update: Comparison Of 5 CP-690,550 Doses Vs. Placebo, For The Treatment Of Rheumatoid Arthritis In Japan [Phase 2]

View source ↗

Summary

Pfizer-sponsored Phase 2 trial in Japan evaluating five doses of CP-690,550 (tofacitinib) vs placebo for rheumatoid arthritis has completed and results are post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• CP-690,550 (tofacitinib)

Snippet

Sponsor: Pfizer | Conditions: Arthritis, Rheumatoid | Phase 2 | Status: COMPLETED | Results posted: 2012-12-25